Joan Butler
Psychiatric/Mental Health · Mesa, AZNPI 1023352952
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 315 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 315 payments — averaging $26.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Alkermes, Inc.$2K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$963
- Johnson & Johnson$553
- Neurocrine Biosciences, Inc.$432
- plus $2K from 12 others
What the payments were for
- Food & beverage$8,08998%
- Education$1352%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 82 | $1,686 |
| Alkermes, Inc. | 46 | $1,653 |
| AbbVie | 66 | $1,260 |
| Otsuka America Pharmaceutical, Inc. | 32 | $963 |
| Johnson & Johnson | 10 | $553 |
| Neurocrine Biosciences, Inc. | 6 | $432 |
| Lundbeck LLC | 19 | $339 |
| Teva Pharmaceuticals USA, Inc. | 3 | $272 |
| Corium, LLC | 8 | $229 |
| Vanda Pharmaceuticals Inc. | 6 | $137 |
| Axsome Therapeutics, Inc. | 3 | $135 |
| E.r. Squibb & Sons, L.L.C. | 3 | $122 |
| Sunovion Pharmaceuticals Inc. | 15 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $108 |
| Almatica Pharma LLC | 5 | $93 |
| Idorsia Pharmaceuticals US Inc | 2 | $64 |
| Ironshore Pharmaceuticals Inc. | 2 | $42 |
| Vertical Pharmaceuticals, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,412
- ARISTADA$1,346
- CAPLYTA$574
- VRAYLAR$495
- ARISTADA INITIO$337
- INGREZZA$259
- SPRAVATO$249
- REXULTI$231
- INVEGA$128
- ABILIFY MAINTENA$124
- ABILIFY ASIMTUFII$124
- Austedo XR$117
- Auvelity$116
How this compares
$8,224 in reported general payments places this provider in the 95th percentile of 1,230 psychiatric/mental health providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 44 | $69,584 |
| AristadaAripiprazole Lauroxil | 14 | $44,927 |
| TrintellixVortioxetine Hydrobromide | 35 | $22,022 |
| VyvanseLisdexamfetamine Dimesylate | 21 | $8,230 |
| MydayisDextroamphetamine/Amphetamine | 12 | $4,533 |
| ConcertaMethylphenidate Hcl | 13 | $4,120 |
| Duloxetine Hcl | 111 | $3,311 |
| Bupropion XlBupropion Hcl | 154 | $3,291 |
| Aripiprazole | 127 | $3,281 |
| Lisdexamfetamine Dimesylate | 15 | $3,270 |
| Oxcarbazepine | 14 | $2,749 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 80 | $2,695 |
| Paliperidone ErPaliperidone | 14 | $2,548 |
| Mirtazapine | 112 | $2,373 |
| Methylphenidate ErMethylphenidate Hcl | 24 | $1,791 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,260 | $69,58444 claims |
| Alkermes, Inc.Aristada | $1,653 | $44,92714 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $108 | $30,25256 claims |
| Johnson & JohnsonConcerta | $553 | $4,12013 claims |
| Almatica Pharma LLCSertraline Hcl | $93 | $1,16795 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,230 psychiatric/mental health providers in Arizona.
Other psychiatric/mental health in Mesa
- Stacy UnderwoodMesa$252K
- Jesika McKenzieMesa$36K
- Gail ZivMesa$29K
- Rebecca DepalmaMesa$19K
- Richard BealsMesa$10K
- Troy FultonMesa$9K
- Julie AngileriMesa$6K
- Ana WilliamsMesa$6K
- Elizabeth ElliottPhoenix$363K
- Diane StrickerGilbert$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.